Australian Department of Home Affairs’ New Biometric System Goes Live Using Unisys Stealth(identity)™ and IDEMIA Biometrics
3.6.2020 13:48:00 EEST | Business Wire | Press release
Unisys Corporation (NYSE: UIS) and IDEMIA today announced that the Australian Department of Home Affairs’ new Enterprise Biometric Identification Services (EBIS) system has gone live. EBIS is based on the Unisys Stealth(identity)™ multi-factor identity management and authentication solution and, using IDEMIA’s facial and fingerprint recognition algorithms, is one of the world’s most accurate biometric identity management systems used for visa and border processing to secure Australia’s’ borders and facilitate the flow of legitimate travellers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005403/en/
(Photo: Business Wire)
EBIS will be used by the department to match the facial images and fingerprints of people including those wishing to travel to Australia such as visa applicants and the facial images for citizenship applicants. The system simultaneously facilitates the processing of legitimate travellers and is designed to support anticipated growth in visa applications, border clearances and applications for citizenship over the next 10 years.
In 2019 there was a record annual 9.5 million visitors to Australia, 3.9 million more than 10 years earlier and 220 300 more than the previous year1. To facilitate travellers’ journeys, border clearance staff need to efficiently verify the identities of travellers and confirm they are who they say they are to prevent delays, avoid queues and improve the overall experience for travellers. In the future, EBIS will provide the capability to quickly flag people who may be crossing the border with fraudulent identities.
Unisys designed and implemented the system within 18 months of signing the contract with the department. EBIS is based on the Stealth(identity) multi-factor identity management and authentication solution, which supports face, finger, iris and voice recognition. It is a robust solution designed for high-volume (more than 100,000 transactions daily) and large-scale galleries (more than 100 million records). Stealth(identity) provides the core biometric identity management functionality of EBIS including the user interface, workflows, business rules, identity data and record linking and auditing functionality. EBIS replaces the previous biometrics matching system that was also provided and supported by Unisys for the last 12 years.
Rick Mayhew, vice president and general manager, Unisys Asia Pacific said: “The long term growth in the volume of travellers that will hopefully return after COVID-19, as well as the increased risk of potential terrorist or fraudulent activity, means that effective border security is more important than ever. EBIS provides Home Affairs with greater confidence in verifying an individual’s identity for efficient and early detection of criminals and persons of national security concern who change names and obtain passports using false identities. We have worked closely with the department and our partner IDEMIA, the global leader in Augmented Identity, to deliver one of the world’s leading solutions to help protect Australia’s borders and national assets.”
The core of EBIS’ fingerprint and facial biometric matching solution uses industry-leading biometric matching algorithms from IDEMIA to quickly and accurately match fingerprints and facial images.
IDEMIA’s flagship product Multi Biometric Search Services (MBSS) is a multi-biometric engine that uses face and fingerprint matching algorithms. This product combines high scalability (over 1 billion identities possible) with high availability, which is necessary for mission-critical systems, integrated within IDEMIA’s world-leading biometric algorithms. The product can also include other modalities such as iris recognition, where required.
Tim Ferris, President of IDEMIA Asia Pacific and Senior Vice President for Public Security and Identity, added: “We are thrilled to provide the biometric engine that powers the EBIS solution. This is the continuation of years of IDEMIA’s engagement in the Australian Borders ecosystem. The combined strengths of IDEMIA behind Unisys provide the Department of Home Affairs with a flagship platform to secure the border now and into the future.”
Unisys has extensive experience supporting government departments and agencies in Australia and around the world. More than 240 government agencies worldwide use Unisys solutions. For more information on Unisys' Public Sector solutions, visit http://www.unisys.com.au/industries/government/public-sector.
1 – Australian Bureau of Statistics -
https://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/3401.0Main%20Features13Mar%202020
About Unisys
Unisys is a global information technology company that builds high-performance, security-centric solutions for the most demanding businesses and governments. Unisys offerings include security software and services; digital transformation and workplace services; industry applications and services; and innovative software operating environments for high-intensity enterprise computing. For more information on how Unisys builds better outcomes securely for its clients across the Government, Financial Services and Commercial markets, visit www.unisys.com.au. Follow Unisys on Twitter and LinkedIn.
###
Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005403/en/
Contact information
Emily Nowland, The Impact Agency
+61 2 9519 5411 or +61 0413 942 179, emily@impactagency.com.au
Claire Hosegood, Unisys Asia Pacific
+61 411 253 663, claire.hosegood@au.unisys.com
Press
PR firm: Havas Paris
Hanna Sebbah
+33 (6) 63 73 30 30
idemia@havas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
